{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:30:52Z","timestamp":1790904652379,"version":"4.1.0"},"reference-count":156,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,3,4]]},"DOI":"10.1080\/13543784.2026.2629512","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:44:22Z","timestamp":1770475462000},"page":"223-238","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Triple negative breast cancer: what clinical progress have we seen in the last 5\u2009years?"],"prefix":"10.1080","volume":"35","author":[{"given":"Daniel S.","family":"Peiffer","sequence":"first","affiliation":[{"name":"University of Chicago","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve A.","family":"Hennessy","sequence":"additional","affiliation":[{"name":"University of Chicago","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"University of Chicago","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.5858\/134.7.e48"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27581"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2022.2528"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00565-2"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00197-2"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21863"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1001389"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01392-0"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.002"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1771"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0932692100"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0799"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06052-0"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.001"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3327"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3495"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw067"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189007"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0369"},{"key":"e_1_3_5_34_1","first-page":"381017","article-title":"Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer","author":"Gucalp A","year":"2020","unstructured":"Gucalp A, Boyle LA, Alano T, et al. Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer. J Clin Oncol. 2020:381017\u20131017.","journal-title":"J Clin Oncol"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78798-x"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10983"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2481"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.006"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30450-3"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00368"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0465"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2257"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0425-1"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0068"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0009-7"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30111-6"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4103"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00712-9"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx440.005"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-PD5-03"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.14028"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2020.151634"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv571"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy517"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253654"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0078-7"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1490854"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189193"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03725-4"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.004"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30904-X"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4499-7"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143361"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35270"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00747-x"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.598877"},{"key":"e_1_3_5_77_1","first-page":"Abstract PS3","volume-title":"Presented at: 2024 San Antonio Breast Cancer Symposium","author":"Wang X","year":"2024","unstructured":"Wang X, Ouyang Q, Tian C, et al. Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for triple-negative breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; San Antonio, TX; 2024 Dec 10\u201313. p. Abstract PS3\u201305."},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02307-3"},{"key":"e_1_3_5_79_1","volume-title":"Presented at: 2024 San Antonio Breast Cancer Symposium","author":"Wu J","year":"2024","unstructured":"Wu J, Zhang J, Tong Z, et al. Interim overall survival of patients with locally advanced or metastatic triple-negative breast cancer treated with first-line PM8002\/BNT327 in combination with nab-paclitaxel in phase 1b\/2 study. Presented at: 2024 San Antonio Breast Cancer Symposium; San Antonio, TX; 2024 Dec 10\u201313. Abstract PS3-08."},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.10.020"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.05.020"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1777046"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.006"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.001"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06230-z"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.009"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113953"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.012"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03267-1"},{"key":"e_1_3_5_90_1","unstructured":"UNC Lineberger Comprehensive Cancer Center.\u202fUNC. Lineberger awarded up to $28M to develop an adaptive clinical trial for metastatic breast cancer.\u202fUNC Lineberger website. 2025 Jun 17 [cited 2025 Nov 30]. Available from: https:\/\/unclineberger.org\/news\/unc-lineberger-awarded-up-to-28m-to-develop-an-adaptive-clinical-trial-for-metastatic-breast-cancer\/"},{"key":"e_1_3_5_91_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: breast cancer. Version 1. 2024. Available from: https:\/\/www.nccn.org"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz235"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33137-4"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.4147"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01506"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.0572"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70160-3"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy460"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.009"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS5-01"},{"key":"e_1_3_5_103_1","volume-title":"Presented at: 2024 San Antonio Breast Cancer Symposium","author":"Dent R","year":"2024","unstructured":"Dent R, Schmid P, Cort\u00e9s J, et al. PS12-09: neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk, early-stage triple-negative breast cancer: overall survival and subgroup results from the phase 3 KEYNOTE-522 study. Presented at: 2024 San Antonio Breast Cancer Symposium; San Antonio, TX; 2024 Dec 10\u201313."},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.6650"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.503"},{"key":"e_1_3_5_106_1","first-page":"GS3","volume-title":"Presented at: San Antonio Breast Cancer Conference","author":"Geyer C","year":"2024","unstructured":"Geyer C. GS3-05: NSABP B-59\/GBG-96-GeparDouze: a randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with stage II and III triple-negative breast cancer. Presented at: San Antonio Breast Cancer Conference; San Antonio, TX; 2024 Dec 10\u201313. p. GS3\u201305."},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645"},{"key":"e_1_3_5_108_1","first-page":"GS1","volume-title":"Presented at: San Antonio Breast Cancer Conference","author":"Garber J","year":"2024","unstructured":"Garber J. OlympiA-Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/germline BRCA1\/BRCA2 pathogenic variants & high risk HER2-negative primary breast cancer; longer term follow.-up. Presented at: San Antonio Breast Cancer Conference; San Antonio, TX; 2024 Dec 10\u201313. p. GS1\u201309."},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000173"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00386-1"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.26886"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA500"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2241"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2229101"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0708"},{"key":"e_1_3_5_118_1","volume-title":"Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting","author":"Tolaney SM","year":"2023","unstructured":"Tolaney SM, DeMichele A, Takano T, et al. ASCENT-05\/OptimICE-RD (AFT-65): phase 3, randomized, open-label study of adjuvant sacituzumab govitecan + pembrolizumab vs pembrolizumab \u00b1 capecitabine in patients with triple-negative breast cancer and residual disease after neoadjuvant therapy and surgery [poster TPS619]. In: DeMichele A, editor. Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, (IL), USA; 2023 Jun 4."},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.480"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.018"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251316176"},{"key":"e_1_3_5_122_1","volume-title":"Presented at. SABCS","author":"Isaacs C","year":"2022","unstructured":"Isaacs C, Nanda R, Yau C, et al. GS5-03: evaluation of anti-PD-1 cemiplimab plus anti-LAG-3 REGN3767 in early-stage, pHigh-risk HER2-negative breast cancer: results from the neoadjuvant I-SPY 2 trial. Presented at. SABCS; San Antonio (TX); 2022 Dec 6\u201310."},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0762"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1021"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03443"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26576"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-6020-5_13"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02151"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4318"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109"},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01455"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02478-2"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.277"},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100032"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909"},{"key":"e_1_3_5_144_1","volume-title":"Presented at: 2025 ESMO Congress","author":"Dent R","year":"2025","unstructured":"Dent R, Shao Z, Schmid P, et al. First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: primary results from the randomised, phase 3 TROPION-Breast02 trial. Presented at: 2025 ESMO Congress. Berlin (GR); 2025 Oct 17\u201321. Abstract LBA21."},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.801"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25830"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1860"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1106"},{"key":"e_1_3_5_153_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.1023"},{"key":"e_1_3_5_154_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.3068"},{"key":"e_1_3_5_155_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1005"},{"key":"e_1_3_5_156_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00882"},{"key":"e_1_3_5_157_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.104"},{"key":"e_1_3_5_158_1","volume-title":"Presented at: 2024 San Antonio Breast Cancer Symposium","author":"Wang X","year":"2024","unstructured":"Wang X, Ouyang Q, Tian C, et al. Evaluation of the safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for triple-negative breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; San Antonio, TX; 2024 Dec 10\u201313. Abstract PS3-05."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2629512","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:49:38Z","timestamp":1773402578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2629512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"alternative-id":["10.1080\/13543784.2026.2629512"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2629512","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}